LGND
Income statement / Annual
Last year (2024), Ligand Pharmaceuticals Incorporated's total revenue was $167.13 M,
an increase of 27.28% from the previous year.
In 2024, Ligand Pharmaceuticals Incorporated's net income was -$4.03 M.
See Ligand Pharmaceuticals Incorporated,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$167.13 M |
$131.31 M |
$196.25 M |
$241.54 M |
$163.56 M |
$120.28 M |
$251.45 M |
$141.10 M |
$108.97 M |
$71.91 M |
| Cost of Revenue |
$11.07 M
|
$35.05 M
|
$52.83 M
|
$62.18 M
|
$30.42 M
|
$11.35 M
|
$6.34 M
|
$5.37 M
|
$5.57 M
|
$5.81 M
|
| Gross Profit |
$156.06 M
|
$96.27 M
|
$143.42 M
|
$179.37 M
|
$133.14 M
|
$108.94 M
|
$245.12 M
|
$135.74 M
|
$103.40 M
|
$66.11 M
|
| Gross Profit Ratio |
0.93
|
0.73
|
0.73
|
0.74
|
0.81
|
0.91
|
0.97
|
0.96
|
0.95
|
0.92
|
| Research and Development Expenses |
$21.43 M
|
$24.54 M
|
$36.08 M
|
$32.11 M
|
$40.50 M
|
$55.91 M
|
$27.86 M
|
$26.89 M
|
$21.22 M
|
$13.38 M
|
| General & Administrative Expenses |
$78.65 M
|
$52.79 M
|
$70.06 M
|
$46.79 M
|
$60.01 M
|
$41.88 M
|
$37.73 M
|
$28.65 M
|
$26.62 M
|
$24.38 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$78.65 M
|
$52.79 M
|
$70.06 M
|
$46.79 M
|
$60.01 M
|
$41.88 M
|
$37.73 M
|
$28.65 M
|
$26.62 M
|
$24.38 M
|
| Other Expenses |
$78.59 M
|
$7.00 M
|
$34.24 M
|
-$3.38 M
|
-$4.87 M
|
-$795.93 M
|
$15.79 M
|
$12.12 M
|
$10.64 M
|
$0.00
|
| Operating Expenses |
$178.67 M
|
$84.32 M
|
$140.38 M
|
$75.52 M
|
$95.64 M
|
-$698.14 M
|
$81.39 M
|
$67.66 M
|
$58.49 M
|
$37.76 M
|
| Cost And Expenses |
$189.74 M
|
$119.37 M
|
$193.21 M
|
$137.69 M
|
$126.06 M
|
-$686.79 M
|
$87.73 M
|
$73.03 M
|
$64.06 M
|
$43.57 M
|
| Interest Income |
$8.06 M
|
$7.71 M
|
$2.05 M
|
$886.00 K
|
$8.08 M
|
$28.43 M
|
$14.00 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$3.04 M
|
$656.00 K
|
$1.80 M
|
$19.62 M
|
$27.42 M
|
$35.75 M
|
$48.28 M
|
$11.40 M
|
$12.18 M
|
$11.80 M
|
| Depreciation & Amortization |
$35.24 M
|
$36.52 M
|
$43.39 M
|
$50.95 M
|
$27.97 M
|
$43.73 M
|
$16.69 M
|
$12.52 M
|
$11.29 M
|
$2.63 M
|
| EBITDA |
$40.79 M |
$100.84 M |
$81.20 M |
$142.77 M |
$56.67 M |
$876.12 M |
$238.30 M |
$81.15 M |
$55.18 M |
$29.96 M |
| EBITDA Ratio |
0.24
|
0.77
|
0.41
|
0.59
|
0.35
|
7.28
|
0.95
|
0.58
|
0.51
|
0.42
|
| Operating Income Ratio |
-0.14
|
0.09
|
0.02
|
0.43
|
0.23
|
6.71
|
0.65
|
0.48
|
0.4
|
0.38
|
| Total Other Income/Expenses Net |
$25.12 M
|
$51.72 M
|
$32.97 M
|
-$31.65 M
|
-$36.21 M
|
-$10.44 M
|
$9.60 M
|
-$10.85 M
|
-$35.93 M
|
$8.00 M
|
| Income Before Tax |
$2.52 M
|
$63.66 M
|
$36.01 M
|
$72.21 M
|
$1.29 M
|
$796.64 M
|
$173.33 M
|
$57.23 M
|
$7.96 M
|
$35.33 M
|
| Income Before Tax Ratio |
0.02
|
0.48
|
0.18
|
0.3
|
0.01
|
6.62
|
0.69
|
0.41
|
0.07
|
0.49
|
| Income Tax Expense |
$6.55 M
|
$9.84 M
|
$41.23 M
|
-$4.15 M
|
-$5.31 M
|
$167.34 M
|
$30.01 M
|
$44.68 M
|
$10.33 M
|
-$219.60 M
|
| Net Income |
-$4.03 M
|
$52.15 M
|
-$33.36 M
|
$57.14 M
|
-$2.99 M
|
$629.30 M
|
$143.32 M
|
$12.56 M
|
-$1.64 M
|
$257.31 M
|
| Net Income Ratio |
-0.02
|
0.4
|
-0.17
|
0.24
|
-0.02
|
5.23
|
0.57
|
0.09
|
-0.02
|
3.58
|
| EPS |
-0.22 |
3.02 |
-1.98 |
3.46 |
-0.18 |
33.13 |
5.96 |
0.6 |
-0.0785 |
13 |
| EPS Diluted |
-0.22 |
2.94 |
-1.98 |
3.34 |
-0.18 |
31.85 |
5.96 |
0.53 |
-0.0785 |
12.12 |
| Weighted Average Shares Out |
$18.29 M
|
$17.30 M
|
$16.87 M
|
$16.63 M
|
$16.19 M
|
$19.00 M
|
$24.05 M
|
$21.03 M
|
$20.83 M
|
$19.79 M
|
| Weighted Average Shares Out Diluted |
$18.29 M
|
$17.76 M
|
$16.87 M
|
$17.25 M
|
$16.19 M
|
$19.76 M
|
$24.07 M
|
$23.48 M
|
$20.83 M
|
$21.23 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
